Compare
Rybrevant vs. Tagrisso

Rybrevant (amivantamab-vmjw) is an injectable medication used for adults with non-small cell lung cancer (NSCLC) with certain mutations in the epidermal growth factor receptor (EGFR) gene. The medication is given as an intravenous infusion through your vein (IV), and how often you receive it depends on what you’re being treated for. You also might receive it with other cancer medications. Some common side effects of Rybrevant (amivantamab) include infusion-related reactions, rash, feeling tired, and infected skin around the nail.

Adults with locally advanced or metastatic NSCLC with certain EGFR mutations:

• In combination with lazertinib as a first-choice treatment
• In combination with carboplatin and pemetrexed as a second-choice treatment for those whose condition has worsened or didn't respond well to EGFR tyrosine kinase inhibitor
• In combination with carboplatin and pemetrexed as a first-choice treatment
• Given alone for those whose condition has worsened or didn’t respond well to platinum-based chemotherapy

• Rash
• Infected skin around the nail
• Muscle and joint pain
• Sores in the mouth
• Swelling of hands, ankles, feet, face, or all of your body
• Unusual feeling in the skin (such as tingling or a crawling feeling)
• Feeling very tired
• Diarrhea
• Constipation
• COVID-19
• Dry skin
• Bleeding
• Decreased appetite
• Itchy skin
• Nausea
• Changes in certain blood tests
• Vomiting
• Shortness of breath
• Cough

Note: The side effects listed above reflect reports from clinical studies where Rybrevant (amivantamab) was given alone or with other medications.

• Infusion-related reactions
• Lung problems
• Blood clots (if used in combination with lazertinib)
• Skin problems
• Eye problems
• Harm to the unborn baby

Tagrisso (osimertinib) is a prescription tablet used to treat adults with certain types of non-small-cell lung cancer (NSCLC) with a specific mutation in the EGFR gene. It’s FDA approved for use in early-stage cases after surgery, as well as in advanced and metastatic stages. This medication is an EGFR inhibitor that helps slow the growth and spread of cancer cells. It’s typically taken once a day by mouth, with or without food. Common side effects include low blood cell counts, diarrhea, and rash.

Non-small-cell lung cancer (NSCLC) in adults with specific EGFR mutations, including:

• Early-stage NSCLC after surgery to remove the tumor
• Advanced NSCLC that can’t be removed by surgery, if the cancer hasn’t gotten worse with platinum-based chemotherapy and radiation therapy
• Metastatic NSCLC as the first treatment
• Advanced or metastatic NSCLC as a first treatment taken together with pemetrexed and platinum-based chemotherapy
• Metastatic NSCLC that’s longer responding to other EGFR inhibitors

• Low white blood cell count (up to 65%)
• Low platelet count (53%)
• Low red blood cell count (52%)
• Diarrhea (47%)
• Skin rash (46%)
• Muscle pain (38%)
• Nail changes (34%)
• Dry skin (32%)
• Mouth sores (24%)
• Tiredness (21%)

• Lung problems
• Heart rhythm problem (QT prolongation)
• Heart problems
• Eye problems
• Skin problems
• Inflammation of the blood vessels in your skin
• Blood and bone marrow problems
• Harm to unborn baby